Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 783,923 |
|
|||||
| News | - | ||||||
| Day High | 3.87 | Low High |
|||||
| Day Low | 3.51 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Mural Oncology PLC | MURA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.26 | 7.2% | 3.87 | 00:00:05 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.56 | 3.51 | 3.87 | 3.66 | 3.61 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,934 | 783,923 | $ 3.61 | $ 2,832,469 | - | 3.40 - 17.00 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:43:30 | 1 | $ 3.70 | USD |
Mural Oncology PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 64.58M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mural Oncology News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MURA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.55 | 4.25 | 3.50 | 3.76 | 926,809 | 0.32 | 9.01% |
| 1 Month | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
| 3 Months | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
| 6 Months | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
| 1 Year | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
| 3 Years | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
| 5 Years | 16.69 | 17.00 | 3.40 | 4.06 | 1,496,904 | -12.82 | -76.81% |
Mural Oncology Description
| Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab. |
